Search

Your search keyword '"Ballen, K."' showing total 296 results
Start Over Author "Ballen, K."
296 results on '"Ballen, K."'

1. Toward CUPID-1T

Author

Armatol, A., Augier, C., Avignone III, F. T., Azzolini, O., Balata, M., Ballen, K., Barabash, A. S., Bari, G., Barresi, A., Baudin, D., Bellini, F., Benato, G., Beretta, M., Bettelli, M., Biassoni, M., Billard, J., Boldrini, V., Branca, A., Brofferio, C., Bucci, C., Camilleri, J., Capelli, C., Capelli, S., Cappelli, L., Cardani, L., Carniti, P., Casali, N., Celi, E., Chang, C., Chiesa, D., Clemenza, M., Colantoni, I., Copello, S., Craft, E., Cremonesi, O., Creswick, R. J., Cruciani, A., D'Addabbo, A., D'Imperio, G., Dabagov, S., Dafinei, I., De Jesus, M., de Marcillac, P., Dell'Oro, S., Di Domizio, S., Di Lorenzo, S., Dixon, T., Dompè, V., Drobizhev, A., Dumoulin, L., Fantini, G., Faverzani, M., Ferri, E., Ferri, F., Ferroni, F., Figueroa-Feliciano, E., Foggetta, L., Formaggio, J., Franceschi, A., Fu, C., Fu, S., Fujikawa, B. K., Gallas, A., Gascon, J., Ghislandi, S., Giachero, A., Gianvecchio, A., Gironi, L., Giuliani, A., Gorla, P., Gotti, C., Grant, C., Gras, P., Guillaumon, P. V., Gutierrez, T. D., Han, K., Hansen, E. V., Heeger, K. M., Helis, D., Helis, D. L., Huang, H. Z., Huang, R. G., Imbert, L., Johnston, J., Juillard, A., Karapetrov, G., Keppel, G., Khalife, H., Kobychev, V. V., Kolomensky, Yu. G., Konovalov, S. I., Kowalski, R., Langford, T., Liu, R., Liu, Y., Loaiza, P., Ma, L., Madhukuttan, M., Mancarella, F., Marini, L., Marnieros, S., Martinez, M., Maruyama, R. H., Mauri, B., Mayer, D., Mazzitelli, G., Mei, Y., Milana, S., Morganti, S., Napolitano, T., Nastasi, M., Nikkel, J., Nisi, S., Nones, C., Norman, E. B., Novosad, V., Nutini, I., O'Donnell, T., Olivieri, E., Olmi, M., Ouellet, J. L., Pagan, S., Pagliarone, C., Pagnanini, L., Pattavina, L., Pavan, M., Peng, H., Pessina, G., Pettinacci, V., Pira, C., Pirro, S., Poda, D. V., Polischuk, O. G., Ponce, I., Pozzi, S., Previtali, E., Puiu, A., Quitadamo, S., Ressa, A., Rizzoli, R., Rosenfeld, C., Rosier, P., Scarpaci, J., Schmidt, B., Sharma, V., Shlegel, V., Singh, V., Sisti, M., Slocum, P., Speller, D., Surukuchi, P. T., Taffarello, L., Tomei, C., Torres, J., Tretyak, V. I., Tsymbaliuk, A., Velazquez, M., Vetter, K. J., Wagaarachchi, S. L., Wang, G., Wang, L., Wang, R., Welliver, B., Wilson, J., Wilson, K., Winslow, L. A., Xue, M., Yan, L., Yang, J., Yefremenko, V., Umatov, V. I., Zarytskyy, M. M., Zhang, J., Zolotarova, A., and Zucchelli, S.

Subjects
Nuclear Experiment
Abstract

Current experiments to search for broken lepton-number symmetry through the observation of neutrinoless double-beta decay ($0\mathrm{\nu\beta\beta}$) provide the most stringent limits on the Majorana nature of neutrinos and the effective Majorana neutrino mass ($m_{\beta\beta}$). The next-generation experiments will focus on the sensitivity to the $0\mathrm{\nu\beta\beta}$ half-life of $\mathcal{O}(10^{27}$--$10^{28}$~years$)$ and $m_{\beta\beta}\lesssim15$~meV, which would provide complete coverage of the so-called Inverted Ordering region of the neutrino mass parameter space. By taking advantage of recent technological breakthroughs, new, future calorimetric experiments at the 1-ton scale can increase the sensitivity by at least another order of magnitude, exploring the large fraction of the parameter space that corresponds to the Normal neutrino mass ordering. In case of a discovery, such experiments could provide important insights toward a new understanding of the mechanism of $0\mathrm{\nu\beta\beta}$. We present here a series of projects underway that will provide advancements in background reduction, cryogenic readout, and physics searches beyond $0\mathrm{\nu\beta\beta}$, all moving toward the next-to-next generation CUPID-1T detector., Comment: contribution to Snowmass 2021

Published
2022

2. Optimization of the first CUPID detector module

Author

CUPID collaboration, Armatol, A., Augier, C., Avignone III, F. T., Azzolini, O., Balata, M., Ballen, K., Barabash, A. S., Bari, G., Barresi, A., Baudin, D., Bellini, F., Benato, G., Beretta, M., Bettelli, M., Biassoni, M., Billard, J., Boldrini, V., Branca, A., Brofferio, C., Bucci, C., Camilleri, J., Capelli, C., Capelli, S., Cappelli, L., Cardani, L., Carniti, P., Casali, N., Celi, E., Chang, C., Chiesa, D., Clemenza, M., Colantoni, I., Copello, S., Craft, E., Cremonesi, O., Creswick, R. J., Cruciani, A., D'Addabbo, A., D'Imperio, G., Dabagov, S., Dafinei, I., Danevich, F. A., De Jesus, M., de Marcillac, P., Dell'Oro, S., Di Domizio, S., Di Lorenzo, S., Dixon, T., Dompè, V., Drobizhev, A., Dumoulin, L., Fantini, G., Faverzani, M., Ferri, E., Ferri, F., Ferroni, F., Figueroa-Feliciano, E., Foggetta, L., Formaggio, J., Franceschi, A., Fu, C., Fu, S., Fujikawa, B. K., Gallas, A., Gascon, J., Ghislandi, S., Giachero, A., Gianvecchio, A., Gironi, L., Giuliani, A., Gorla, P., Gotti, C., Grant, C., Gras, P., Guillaumon, P. V., Gutierrez, T. D., Han, K., Hansen, E. V., Heeger, K. M., Helis, D. L., Huang, H. Z., Huang, R. G., Imbert, L., Johnston, J., Juillard, A., Karapetrov, G., Keppel, G., Khalife, H., Kobychev, V. V., Kolomensky, Yu. G., Konovalov, S. I., Kowalski, R., Langford, T., Lefevre, M ., Liu, R., Liu, Y., Loaiza, P., Ma, L., Madhukuttan, M., Mancarella, F., Marini, L., Marnieros, S., Martinez, M., Maruyama, R. H., Mas, Ph., Mauri, B., Mayer, D., Mazzitelli, G., Mei, Y., Milana, S., Morganti, S., Napolitano, T., Nastasi, M., Nikkel, J., Nisi, S., Nones, C., Norman, E. B., Novosad, V., Nutini, I., O'Donnell, T., Olivieri, E., Olmi, M., Ouellet, J. L., Pagan, S., Pagliarone, C., Pagnanini, L., Pattavina, L., Pavan, M., Peng, H., Pessina, G., Pettinacci, V., Pira, C., Pirro, S., Poda, D. V., Polischuk, O. G., Ponce, I., Pozzi, S., Previtali, E., Puiu, A., Quitadamo, S., Ressa, A., Rizzoli, R., Rosenfeld, C., Rosier, P., Scarpaci, J., Schmidt, B., Sharma, V., Shlegel, V., Singh, V., Sisti, M., Slocum, P., Speller, D., Surukuchi, P. T., Taffarello, L., Tomei, C., Torres, J., Tretyak, V. I., Tsymbaliuk, A., Velazquez, M., Vetter, K. J., Wagaarachchi, S. L., Wang, G., Wang, L., Wang, R., Welliver, B., Wilson, J., Wilson, K., Winslow, L. A., Xue, M., Yan, L., Yang, J., Yefremenko, V., Umatov, V. I., Zarytskyy, M. M., Zhang, J., Zolotarova, A., and Zucchelli, S.

Subjects
Physics - Instrumentation and Detectors, Nuclear Experiment
Abstract

CUPID will be a next generation experiment searching for the neutrinoless double $\beta$ decay, whose discovery would establish the Majorana nature of the neutrino. Based on the experience achieved with the CUORE experiment, presently taking data at LNGS, CUPID aims to reach a background free environment by means of scintillating Li$_{2}$$^{100}$MoO$_4$ crystals coupled to light detectors. Indeed, the simultaneous heat and light detection allows us to reject the dominant background of $\alpha$ particles, as proven by the CUPID-0 and CUPID-Mo demonstrators. In this work we present the results of the first test of the CUPID baseline module. In particular, we propose a new optimized detector structure and light sensors design to enhance the engineering and the light collection, respectively. We characterized the heat detectors, achieving an energy resolution of (5.9 $\pm$ 0.2) keV FWHM at the $Q$-value of $^{100}$Mo (about 3034 keV). We studied the light collection of the baseline CUPID design with respect to an alternative configuration which features gravity-assisted light detectors' mounting. In both cases we obtained an improvement in the light collection with respect to past measures and we validated the particle identification capability of the detector, which ensures an $\alpha$ particle rejection higher than 99.9%, fully satisfying the requirements for CUPID., Comment: 10 pages, 5 figures

Published
2022

3. Optimization of the first CUPID detector module

Author

collaboration, CUPID, Armatol, A, Augier, C, III, FT Avignone, Azzolini, O, Balata, M, Ballen, K, Barabash, AS, Bari, G, Barresi, A, Baudin, D, Bellini, F, Benato, G, Beretta, M, Bettelli, M, Biassoni, M, Billard, J, Boldrini, V, Branca, A, Brofferio, C, Bucci, C, Camilleri, J, Capelli, C, Capelli, S, Cappelli, L, Cardani, L, Carniti, P, Casali, N, Celi, E, Chang, C, Chiesa, D, Clemenza, M, Colantoni, I, Copello, S, Craft, E, Cremonesi, O, Creswick, RJ, Cruciani, A, D'Addabbo, A, D'Imperio, G, Dabagov, S, Dafinei, I, Danevich, FA, Jesus, M De, Marcillac, P de, Dell'Oro, S, Domizio, S Di, Lorenzo, S Di, Dixon, T, Dompè, V, Drobizhev, A, Dumoulin, L, Fantini, G, Faverzani, M, Ferri, E, Ferri, F, Ferroni, F, Figueroa-Feliciano, E, Foggetta, L, Formaggio, J, Franceschi, A, Fu, C, Fu, S, Fujikawa, BK, Gallas, A, Gascon, J, Ghislandi, S, Giachero, A, Gianvecchio, A, Gironi, L, Giuliani, A, Gorla, P, Gotti, C, Grant, C, Gras, P, Guillaumon, PV, Gutierrez, TD, Han, K, Hansen, EV, Heeger, KM, Helis, DL, Huang, HZ, Huang, RG, Imbert, L, Johnston, J, Juillard, A, Karapetrov, G, Keppel, G, Khalife, H, Kobychev, VV, Kolomensky, Yu G, Konovalov, SI, Kowalski, R, Langford, T, Lefevre, M, Liu, R, Liu, Y, Loaiza, P, Ma, L, and Madhukuttan, M

Subjects
physics.ins-det, nucl-ex
Abstract

CUPID will be a next generation experiment searching for the neutrinolessdouble $\beta$ decay, whose discovery would establish the Majorana nature ofthe neutrino. Based on the experience achieved with the CUORE experiment,presently taking data at LNGS, CUPID aims to reach a background freeenvironment by means of scintillating Li$_{2}$$^{100}$MoO$_4$ crystals coupledto light detectors. Indeed, the simultaneous heat and light detection allows usto reject the dominant background of $\alpha$ particles, as proven by theCUPID-0 and CUPID-Mo demonstrators. In this work we present the results of thefirst test of the CUPID baseline module. In particular, we propose a newoptimized detector structure and light sensors design to enhance theengineering and the light collection, respectively. We characterized the heatdetectors, achieving an energy resolution of (5.9 $\pm$ 0.2) keV FWHM at the$Q$-value of $^{100}$Mo (about 3034 keV). We studied the light collection ofthe baseline CUPID design with respect to an alternative configuration whichfeatures gravity-assisted light detectors' mounting. In both cases we obtainedan improvement in the light collection with respect to past measures and wevalidated the particle identification capability of the detector, which ensuresan $\alpha$ particle rejection higher than 99.9%, fully satisfying therequirements for CUPID.

Published
2022

4. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

Author

Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, null, null, Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, and null, null

Abstract

PURPOSEAllogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit.METHODSAdults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS.RESULTSThree hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P =.0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P =.0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P =.575).CONCLUSIONAlthough the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Published
2024

7. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

Author

Kröger, N M, Deeg, J H, Olavarria, E, Niederwieser, D, Bacigalupo, A, Barbui, T, Rambaldi, A, Mesa, R, Tefferi, A, Griesshammer, M, Gupta, V, Harrison, C, Alchalby, H, Vannucchi, A M, Cervantes, F, Robin, M, Ditschkowski, M, Fauble, V, McLornan, D, Ballen, K, Popat, U R, Passamonti, F, Rondelli, D, and Barosi, G

Published
2015
Full Text
View/download PDF

10. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor

Author

Bachanova, V, Burns, L J, Wang, T, Carreras, J, Gale, R P, Wiernik, P H, Ballen, K K, Wirk, B, Munker, R, Rizzieri, D A, Chen, Y-B, Gibson, J, Akpek, G, Costa, L J, Kamble, R T, Aljurf, M D, Hsu, J W, Cairo, M S, Schouten, H C, Bacher, U, Savani, B N, Wingard, J R, Lazarus, H M, Laport, G G, Montoto, S, Maloney, D G, Smith, S M, Brunstein, C, and Saber, W

Published
2015
Full Text
View/download PDF

23. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: Consensus recommendations from the Acute Leukemia Working Party of the EBMT

Author

Dholaria, B., Savani, B. N., Labopin, M., Luznik, L., Ruggeri, A., Mielke, S., Al Malki, M. M., Kongtim, P., Fuchs, E., Huang, X. -J., Locatelli, Franco, Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Soussan, P. B., Arnault, Y., Handgretinger, R., Roy, D. -C., O'Donnell, P., Bashey, A., Solomon, S., Romee, R., Lewalle, P., Gayoso, J., Maschan, M., Lazarus, H. M., Ballen, K., Giebel, S., Baron, F., Ciceri, F., Esteve, J., Gorin, N. -C., Spyridonidis, A., Schmid, C., Ciurea, S. O., Nagler, A., Mohty, M., Locatelli F. (ORCID:0000-0002-7976-3654), Dholaria, B., Savani, B. N., Labopin, M., Luznik, L., Ruggeri, A., Mielke, S., Al Malki, M. M., Kongtim, P., Fuchs, E., Huang, X. -J., Locatelli, Franco, Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Soussan, P. B., Arnault, Y., Handgretinger, R., Roy, D. -C., O'Donnell, P., Bashey, A., Solomon, S., Romee, R., Lewalle, P., Gayoso, J., Maschan, M., Lazarus, H. M., Ballen, K., Giebel, S., Baron, F., Ciceri, F., Esteve, J., Gorin, N. -C., Spyridonidis, A., Schmid, C., Ciurea, S. O., Nagler, A., Mohty, M., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.

Published
2020

24. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation

Author

Ciurea, S. O., Al Malki, M. M., Kongtim, P., Fuchs, E. J., Luznik, L., Huang, X. -J., Ciceri, F., Locatelli, Franco, Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Ben Soussan, P., Arnault, Y., Handgretinger, R., Roy, D. -C., O'Donnell, P. V., Bashey, A., Solomon, S., Romee, R., Gayoso, J., Lazarus, H. M., Ballen, K., Savani, B. N., Mohty, M., Nagler, A., Locatelli F. (ORCID:0000-0002-7976-3654), Ciurea, S. O., Al Malki, M. M., Kongtim, P., Fuchs, E. J., Luznik, L., Huang, X. -J., Ciceri, F., Locatelli, Franco, Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Ben Soussan, P., Arnault, Y., Handgretinger, R., Roy, D. -C., O'Donnell, P. V., Bashey, A., Solomon, S., Romee, R., Gayoso, J., Lazarus, H. M., Ballen, K., Savani, B. N., Mohty, M., Nagler, A., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

The number of HLA-haploidentical hematopoietic cell transplants continues to increase worldwide due to recent improvements in outcomes, allowing more patients with hematological malignancies and non-malignant disorders to benefit from this procedure and have a chance to cure their disease. Despite these encouraging results, questions remain as multiple donors are usually available for transplantation, and choosing the best HLA-haploidentical donor for transplantation remains a challenge. Several approaches to haploidentical transplantation have been developed over time and, based on the graft received, can be grouped as follows: T-cell depleted haploidentical transplants, either complete or partial, or with T-cell replete grafts, performed with post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, or G-CSF-primed bone marrow graft and enhanced GVHD prophylaxis. Carefully selecting the donor can help optimize transplant outcomes for recipients of haploidentical donor transplants. Variables usually considered in the donor selection include presence of donor-specific antibodies in the recipient, donor age, donor/recipient gender and ABO combinations, and immunogenic variables, such as natural killer cell alloreactivity or KIR haplotype. Here we provide a comprehensive review of available evidence for selecting haploidentical donors for transplantation, and summarize the recommendations from the European Society for Blood and Marrow Transplantation (EBMT) on donor selection for different transplant platforms.

Published
2020

33. Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation (Bone Marrow Transplantation, (2018), 53, 5, (521-534), 10.1038/s41409-017-0062-8)

Author

Ciurea, S. O., Cao, K., Fernandez-Vina, M., Kongtim, P., Malki, M. A., Fuchs, E., Luznik, L., Huang, X. -J., Ciceri, F., Locatelli, Franco, Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Handgretinger, R., Roy, D. -C., O'Donnell, P., Bashey, A., Lazarus, H. M., Ballen, K., Savani, B. N., Mohty, M., Nagler, A., Locatelli F. (ORCID:0000-0002-7976-3654), Ciurea, S. O., Cao, K., Fernandez-Vina, M., Kongtim, P., Malki, M. A., Fuchs, E., Luznik, L., Huang, X. -J., Ciceri, F., Locatelli, Franco, Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Handgretinger, R., Roy, D. -C., O'Donnell, P., Bashey, A., Lazarus, H. M., Ballen, K., Savani, B. N., Mohty, M., Nagler, A., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

The original version of this Article contained a typographical error in the spelling of the author Marcelo Fernandez-Vina, which was incorrectly given as Marcelo Fernadez-Vina. This has now been corrected in the PDF and HTML versions of the Article.

Published
2019

35. Stem Cell Engraftment Strategies

Author

QUESENBERRY, P. J., STEWART, F. M., BECKER, P., D'HONDT, LIONEL, FRIMBERGER, A., LAMBERT, J. F., COLVIN, G. A., MILLER, C., HEYES, C., ABEDI, MERHDAD, DOONER, M., CARLSON, J., REILLY, J., McAULIFFE, C., STENCEL, K., BALLEN, K., EMMONS, R., DOYLE, P., ZHONG, S., WANG, H., and HABIBIAN, H.

Published
2001

36. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation

Author

Ciurea, S. O., Cao, K., Fernadez-Vina, M., Kongtim, P., Malki, M. A., Fuchs, E., Luznik, L., Huang, X. -J., Ciceri, F., Locatelli, Franco, Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Handgretinger, R., Roy, D. -C., O'Donnell, P., Bashey, A., Lazarus, H. M., Ballen, K., Savani, B. N., Mohty, M., Nagler, A., Locatelli F. (ORCID:0000-0002-7976-3654), Ciurea, S. O., Cao, K., Fernadez-Vina, M., Kongtim, P., Malki, M. A., Fuchs, E., Luznik, L., Huang, X. -J., Ciceri, F., Locatelli, Franco, Aversa, F., Castagna, L., Bacigalupo, A., Martelli, M., Blaise, D., Handgretinger, R., Roy, D. -C., O'Donnell, P., Bashey, A., Lazarus, H. M., Ballen, K., Savani, B. N., Mohty, M., Nagler, A., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Haploidentical donors are now increasingly considered for transplantation in the absence of HLA-matched donors or when an urgent transplant is needed. Donor-specific anti-HLA antibodies (DSA) have been recently recognized as an important barrier against successful engraftment of donor cells, which can affect transplant survival. DSA appear more prevalent in this type of transplant due to higher likelihood of alloimmunization of multiparous females against offspring's HLA antigens, and the degree of mismatch. Here we summarize the evidence for the role of DSA in the development of primary graft failure in haploidentical transplantation and provide consensus recommendations from the European Society for Blood and Marrow Transplant Group on testing, monitoring, and treatment of patients with DSA receiving haploidentical hematopoietic progenitor cell transplantation.

Published
2018

38. America's most admired corporations.

Author

Ballen, K.

Subjects
VALUATION of corporations
Abstract

Presents `Fortune' magazine's tenth annual survey of American's most admired corporations. The top ten is an elite club with just over 30 corporate members over the decade; Pharmaceutical giant, Merck, has made the cut every year; Merck's ranking as No. 1; Levi Strauss, as the newest recruit to the top ten; RJR Nabisco, as the big winner with a 29 percent score increase; Eight key attributes of reputation; Rankings; More. INSET: How it was done (`Fortune's' system of ranking)..

Published
1992

39. Stem cells and prenatal origin of breast cancer

Author

Baik, I Becker, PS DeVito, WJ Lagiou, P Ballen, K and Quesenberry, PJ Hsieh, CC

Abstract

The hypothesis that in utero exposure to pregnancy hormones, notably estrogens, is related to the occurrence of breast cancer in the offspring has been examined in a number of epidemiological and experimental studies. Many studies have provided direct or indirect evidence that supports the hypothesis of an intrauterine component in the origin of breast cancer. Human studies to examine the underlying biological mechanisms, however, have been limited. We review the likely role of stem cells in hormone-mediated carcinogenic process, particularly as intermediate steps between in utero exposure to hormones and breast cancer. We summarize also studies related to the assumptions of the hypothesis concerning in utero exposure. We propose the use of stem cell potential as a measurable variable of the ‘fertile soil’, a term that has been used to characterize the consequences of fetal exposure to intrauterine environment. We conclude by outlining a feasible population-based study that measures stem cell potential to explore mechanisms mediating the relation between in utero exposure to pregnancy hormones and breast cancer risk in the offspring.

Published
2004

40. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor

Author

Bachanova, V, primary, Burns, L J, additional, Wang, T, additional, Carreras, J, additional, Gale, R P, additional, Wiernik, P H, additional, Ballen, K K, additional, Wirk, B, additional, Munker, R, additional, Rizzieri, D A, additional, Chen, Y-B, additional, Gibson, J, additional, Akpek, G, additional, Costa, L J, additional, Kamble, R T, additional, Aljurf, M D, additional, Hsu, J W, additional, Cairo, M S, additional, Schouten, H C, additional, Bacher, U, additional, Savani, B N, additional, Wingard, J R, additional, Lazarus, H M, additional, Laport, G G, additional, Montoto, S, additional, Maloney, D G, additional, Smith, S M, additional, Brunstein, C, additional, and Saber, W, additional

Published
2014
Full Text
View/download PDF

41. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia

Author

DeAngelo, D J, primary, Stevenson, K E, additional, Dahlberg, S E, additional, Silverman, L B, additional, Couban, S, additional, Supko, J G, additional, Amrein, P C, additional, Ballen, K K, additional, Seftel, M D, additional, Turner, A R, additional, Leber, B, additional, Howson-Jan, K, additional, Kelly, K, additional, Cohen, S, additional, Matthews, J H, additional, Savoie, L, additional, Wadleigh, M, additional, Sirulnik, L A, additional, Galinsky, I, additional, Neuberg, D S, additional, Sallan, S E, additional, and Stone, R M, additional

Published
2014
Full Text
View/download PDF

42. Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT

Author

Li, L, primary, Kim, H T, additional, Nellore, A, additional, Patsoukis, N, additional, Petkova, V, additional, McDonough, S, additional, Politikos, I, additional, Nikiforow, S, additional, Soiffer, R, additional, Antin, J H, additional, Ballen, K, additional, Cutler, C, additional, Ritz, J, additional, and Boussiotis, V A, additional

Published
2014
Full Text
View/download PDF

45. Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research

Author

Keating, A., primary, DaSilva, G., additional, Perez, W. S., additional, Gupta, V., additional, Cutler, C. S., additional, Ballen, K. K., additional, Cairo, M. S., additional, Camitta, B. M., additional, Champlin, R. E., additional, Gajewski, J. L., additional, Lazarus, H. M., additional, Lill, M., additional, Marks, D. I., additional, Nabhan, C., additional, Schiller, G. J., additional, Socie, G., additional, Szer, J., additional, Tallman, M. S., additional, and Weisdorf, D. J., additional

Published
2012
Full Text
View/download PDF

47. Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes

Author

Glotzbecker, B., primary, Mills, H., additional, Rosenblatt, J., additional, Joyce, R., additional, Levine, J., additional, Tzachanis, D., additional, Stevenson, M., additional, Attar, E., additional, Ballen, K., additional, Chen, Y.-B., additional, Boussiotis, V., additional, Zwicker, J., additional, Luptakova, K., additional, Arnason, J., additional, Bonhoff, J., additional, Delaney, C., additional, Conway, K., additional, Giallombardo, N., additional, Mortellite, J., additional, Fitzgerald, D., additional, O'Brien, S., additional, McMahon, C., additional, Vasir, B., additional, Stroopinsky, D., additional, Spitzer, T., additional, and Avigan, D., additional

Published
2012
Full Text
View/download PDF

48. Immune Reconstitution After Double Umbilical Cord Blood Stem Cell Transplantation: Comparison With Peripheral Blood Stem Cell Transplantation

Author

Jacobson, C., primary, Turki, A., additional, McDonough, S., additional, Stevenson, K., additional, Kim, H., additional, Herrera, M., additional, Reynolds, C., additional, Alyea, E., additional, Ho, V., additional, Koreth, J., additional, Soiffer, R., additional, Antin, J., additional, Ballen, K., additional, Cutler, C., additional, and Ritz, J., additional

Published
2011
Full Text
View/download PDF

49. Anti-HLA Antibodies Predict Graft Failure, Time to Engraftment and Umbilical Cord Unit Dominance in Double Umbilical Cord Blood Transplantation

Author

Cutler, C., primary, Kim, H.T., additional, Sun, L., additional, Sese, D., additional, Kao, G., additional, Vasquez, M., additional, Armand, P., additional, Koreth, J., additional, Ho, V.T., additional, Alyea, E., additional, Soiffer, R.J., additional, Ballen, K., additional, Ritz, J., additional, Milford, E., additional, and Antin, J.H., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results